Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are two subtypes of non-Hodgkin lymphoma. A number of studies have evaluated associations between risk factors and CLL/SLL risk. However, these associations remain inconsistent or lacked confirmation. This may be due, in part, to the inadequate sample size of CLL/SLL cases.
15 186 controls from 13 case-control studies from Europe, North America, and Australia as part of the International Lymphoma Epidemiology Consortium (InterLymph) NHL Subtypes Project. Moreover, we considered exposures not only individually but also jointly to assess independence among exposures.
Methods

Study Population
Detailed methodology for the InterLymph NHL Subtypes Project is provided elsewhere in this issue. Studies eligible for inclusion in this pooled analysis fulfilled the following criteria: 1) case-control design; 2) inclusion of incident CLL/SLL cases with the clonality of the circulating B-cell lymphocytes confirmed by flow cytometry; and 3) availability of individual-level data for at least several risk factors of interest by December 31, 2011 . Most studies excluded individuals with a known history of solid organ transplantation or HIV/AIDS. Contributing studies were approved by local ethics review committees, and all participants provided written, informed consent before interview.
NHL Subtype Ascertainment and Harmonization
Cases were classified according to the World Health Organization classification (13, 14) using guidelines from the InterLymph Pathology Working Group (15, 16) . Most studies had some form of centralized pathology review by at least one expert hematopathologist to confirm the diagnoses. Each participating study's pathology review procedures, rules for NHL subtype classification, and NHL subtype distribution were then reviewed independently by an interdisciplinary team of pathologists and epidemiologists from InterLymph.
Risk Factor Ascertainment and Harmonization
Each study collected data on putative CLL/SLL risk factors in a standardized, structured format by in-person or telephone interviews (typically computer-assisted) or self-administered questionnaires. Risk factors selected for inclusion in this analysis were lifestyle, medical history, family history, and occupational risk factors with data from at least four studies. Centralized harmonization of de-identified, individual-level data from each study was a key element of the project. Each exposure variable was harmonized individually; data were then reviewed for consistency among related exposure variables. Details of the collected data and data harmonization rules are provided elsewhere in this issue.
Statistical Analysis
We first performed analyses to evaluate risk of CLL/SLL with each exposure variable using unconditional logistic regression models adjusted for age, race/ethnicity, sex, and study (i.e., the "basic model"). The statistical significance of each exposure was evaluated by a likelihood ratio test, comparing models with and without the exposure variable of interest, with P values less than 0.05 identifying putatively influential factors. Individuals with missing data for the exposure variable of interest were excluded. To evaluate effect heterogeneity among the 13 studies, we performed a separate logistic regression within each study and then quantified the variability of the coefficients by the H statistic, adapting the definition by Higgins and Thompson to categorical variables (17) . No meaningful heterogeneity was observed (results not shown).
We then examined the relationship between CLL/SLL risk and each putative risk factor considering possible effect modification and accounting for other potential confounders. To consider possible effect modification, we repeated the above logistic regression analyses, but now stratified individuals by age, sex, race/ethnicity, region, study, study design (i.e., population-based versus hospital-or clinic-based), or other putative risk factors identified in the analysis. Forest plots illustrated the results from the stratified analyses to identify possible modifiers of the effect of an exposure variable of interest. No evidence of effect modification was observed (results not shown). To account for other potential confounders, we conducted two analyses. First, we evaluated the risk estimate for each putative risk factor in a series of models that adjusted for one other putative risk factor individually as well as age, race/ethnicity, sex, and study (pairwise adjustment modeling). Second, we conducted a single logistic regression model including all putative risk factors, this time including a separate missing category for each variable to ensure that the whole study population was included in the analysis (i.e., not dropped due to missing data). Finally, we conducted a forward step-wise logistic regression with all putative risk factors, adjusting for age, sex, race/ethnicity, and study, to identify our "full model."
Because controls for most of the 13 studies were frequency matched by age and sex to all cases (e.g., all NHL subtypes) rather than just to CLL/SLL, we conducted sensitivity analyses using a subset of controls from each study that were frequency matched by age and sex to CLL/SLL cases. The results from these sensitivity analyses were very similar to the results obtained using the full set of controls (results not shown); thus, we retained the full set of controls for our main analyses to increase statistical power. Table 1 shows the distribution of the 2440 CLL/SLL cases and 15 186 controls across the 13 participating studies, along with characteristics for age, race/ethnicity, sex, and social economic status. Relative to controls, cases tended to be older (over the age of 60 years) and were more likely to be men. Cases had a median age at diagnosis of 64 years (range 28-93) compared with 60 years (range 17-97) at interview in controls. The majority (>95%) of cases and controls were non-Hispanic whites. There was no evidence of a difference in distribution of social economic status across cases and controls (P = .19).
Results
Basic Model Results
Medical History. Suffering from any atopic condition (including allergy, hay fever, asthma, or eczema) was inversely associated with CLL/SLL risk (odds ratio [OR] = 0.86, 95% confidence interval [CI] = 0.78 to 0.95; Table 2 ). Within specific atopic conditions, similar effect sizes were noted for allergy, food allergy, and hay fever conditions, although not statistically significant for the latter two ( Table 2 ). Little to no evidence of a reduced risk was observed for asthma (OR = 0.99, 95% CI = 0.83 to 1.17) and eczema (OR = 0.96, 95% CI = 0.82 to 1.13). When we excluded individuals who had atopic conditions diagnosed within 2 years of age of CLL/SLL diagnosis or interview, the effects sizes remained consistent for any atopy, (OR = 0.82, 95% CI = 0.72 to 0.93), allergy (OR = 0.83, 95% CI = 0.67 to 1.03), and hay fever (OR = 0.83, 95% CI = 0.69 to 0.99). Having a history of transfusion also was inversely associated with CLL/SLL (OR = 0.79, 95% CI = 0.66 to 0.94; Table 2 ). When we stratified the study sample based on study design, we observed nonsignificant differences in effects between populationbased case-control studies (OR = 0.89, 95% CI = 0.68 to 1.16) and hospital-based case-control studies (OR = 0.71, 95% CI = 0.56 to 0.91). Further, the association was more notable for those who received transfusion after 1990 (OR = 0.68, 95% CI = 0.49 to 0.94). There was also a weak upward trend with adult height (per 10 cm change) when considered as a continuous variable (OR = 1.10, 95% CI = 1.02 to 1.19). We observed no significant associations with CLL/SLL risk with history of any of the specific autoimmune diseases, weight, body mass index, reproductive history, oral contraceptive use, and hormone replacement therapy (results not shown).
As previously published by InterLymph, having a hepatitis C virus seropositivity was strongly associated with CLL/SLL (OR = 2.08, 95% CI = 1.23 to 3.49; Table 2 ).
Family History. As expected, having a family history of any hematological malignancy among first-degree relatives was strongly associated with CLL/SLL risk (OR = 2.17, 95% CI = 1.77 to 2.65; Table 3 ). Risks were also elevated when looking at family history of NHL (OR = 1.92, 95% CI = 1.41 to 2.61) and family history of leukemia (OR = 2.41, 95% CI = 1.85 to 3.14). The risk increased slightly for first-degree relatives who were men compared with women for any family history hematological malignancy. Although not statistically significant (P > .05), the effects were elevated when looking at family history of myeloma (OR = 2.00, 95% CI = 0.92 to 4.34).
Occupation. History of living or working on a farm was significantly associated with CLL/SLL risk (OR = 1.21, 95% CI = 1.07 to 1.36; Table 4 ). However, the association slightly attenuated when evaluating separately history of working on a farm (OR = 1.16, 95% CI = 1.00 to 1.35) or history of living on a farm (OR = 1.12, 95% CI = 0.97 to 1.30). These data were further corroborated with the occupational data. Here, we observed an association with farming occupation (OR = 1.23, 95% CI = 1.04 to 1.45 other occupations analyses were based on limited numbers of cases (Table 4) .
Lifestyle Factors. As in previous InterLymph reports, a moderate inverse association was noted between sun exposure and CLL/ SLL risk, especially for recreational sun exposure (Table 5) . We also observed a modest reduced risk of CLL/SLL in ever cigarette smoking (OR = 0.90, 95% CI = 0.81 to 0.99). This effect was further reduced when looking at current cigarette smoking (OR = 0.82, 95% CI = 0.71 to 0.94; Table 5 ), with a weak nonsignificant inverse trend with cigarettes smoked per day and with duration of smoking. Regular use of hair dyes (by men and women) did not modify the risk of CLL/SLL when evaluating ever use, type of hair dye, color, duration, or frequency (Table 5 ). However, use of hair dyes before 1980 had an increased risk of CLL/SLL (OR = 1.36, 95% CI = 1.0 to 1.86). No evidence of an association was noted for alcohol consumption and physical activity (results not shown).
Full Model Results.
To develop our full model, we selected risk factors that had statistical significance of P values less than .05 in the basic model analyses. However, for those risk factors that had additional variables that captured duration and intensity, we only selected those that had consistent evidence of association across the additional variables. The full model results are shown in Table 6 . There is clear evidence that the selected risk factors are independent of one another with minimal evidence of confounding and interaction. This is evidenced by the minimal change in effect size obtained from the basic models (adjusted only for design variables) compared with that obtained from the full model (adjusted for the design variables and the other selected variables). This is also evidenced by our pairwise adjustment modeling.
Discussion
Individual level data from 2440 CLL cases and 15 186 controls from 13 case-control studies were reanalyzed centrally through the InterLymph consortium to evaluate associations of medical history, family history, lifestyle, and occupational risk factors with CLL/SLL risk. We confirmed prior findings by InterLymph and others with additional cases and controls for a number of exposures. Specifically, we confirmed the previously reported strong increased risk with family history of hematological cancer (10) (11) (12) , the increased risk with height (18, 19) , the increased risk with farming exposures (20) (21) (22) (23) (24) , and the protective effect of UV radiation on CLL/SLL risk (25, 26) . Although we report a significant increased risk with hepatitis C virus herein, we had no additional new data beyond that reported in an earlier InterLymph pooled analysis (27) .
With an additional CLL/SLL cases and controls, we supported an earlier InterLymph finding of a reduction in risk of CLL/SLL with history of any atopic condition (28) . A concern with any association with IgE-mediated exposures, like atopic conditions, is reverse causality such that the inefficient immunological repose to allergens may be due to CLL/SLL disease and therefore explain the observed associations. With the larger sample size, we excluded CLL/SLL cases whose atopic diagnosis was within 10 years of * CI = confidence interval; OR = odds ratio. † OR (95% CI) adjusted for age, sex, race/ethnicity, and study. ‡ Smoked longer than 6 months or more than 100 cigarettes in lifetime. CLL/SLL diagnosis to evaluate the role of reverse causality. The results (not shown) from these additional sensitivity analyses were consistent with the full data and show a risk reduction of 20% among those CLL/SLL cases reporting any atopic disease. Thus, the inverse association is unlikely to be due to reverse causality and suggests that induction of an increase IgE response by environmental exposures could be a factor in CLL/SLL pathogenesis (29) . Future studies will be needed to test this hypothesis. We observed an inverse association between blood transfusion and CLL/SLL. These results were consistent across other transfusion variables including number of transfusions, latency, and timeframe of transfusion (before 1990 or after). However, these results are inconsistent with the hypothesis that pathogens are transmitted through blood transfusion and therefore would presumably increase the risk of CLL/SLL. An earlier meta-analysis of case-control and cohort studies reported an increased risk with CLL/SLL (OR = 1.66, 95% CI = 1.08 to 2.56) (30) . There was very little overlap of studies included in the earlier meta-analysis and the one reported herein. Although our pooled study of individual-level data is a strength, as is our large sample size, we were unable to explain the biologic mechanism behind our findings. Our results may be due to unknown confounding as we lacked details on the type of transfusion or the indication for the transfusion. Our results may also be due to selection bias because the effect was more inversely associated in hospital-based (OR = 0.71) compared with population-based (OR = 0.89) case-control studies.
We report a statistically significant inverse association between current cigarette smoking and CLL/SLL. The effect of this association is modest, but yet consistent across the other smoking variables with dose response relationships observed with pack-years, intensity, and duration of exposure, although not statistically significant for the latter two. In a recent InterLymph pooled study of smoking that included 1156 CLL/SLL cases and 4630 controls from seven case-control studies, which were also included herein, current cigarette smoking was found to have a nonsignificant reduced risk of CLL/SLL (OR = 0.82, 95% CI = 0.67 to 1.01) (31) . With an additional six case-control studies included in this study, we found this effect to remain. Effect estimates from prospective cohort studies have been mixed with both elevated effects (32, 33) and protective effects (34) reported with current cigarette smoking; however, none of these results were significant due to small numbers (n < 500 CLL/SLL cases). The biologic mechanism for this inverse association is unclear, but smoking may affect immune function (35) . Replication of our findings is needed, but given that we observed a significant but weak effect, large sample sizes will be required or alternative approaches, such as evaluating biomarkers of exposure to cigarette smoke on CLL/SLL risk, will be needed.
We have identified an increased risk of CLL/SLL among hairdressers, which has not been previously reported. Hairdressers can be exposed to a wide variety of chemicals including organic solvents, dyes, and ammonia. The International Agency for Research among women (OR = 1.50, 95% CI = 1.10 to 2.00) based on a subset of four case-control studies reported herein (37) . However, with data from nine additional case-control studies, we found a slight attenuation with this finding (OR = 1.36, 95% CI = 1.00 to 1.86). Future studies will need detailed data of hair dye exposure to hone in on the effect of this exposure on CLL/SLL risk. Our study has several strengths, including the ability to harmonize individual-level data, the extensive review of harmonization by workgroups to ensure accuracy, the large number of CLL/SLL cases and controls, and the large number of available exposures to simultaneously evaluate joint effects and perform sensitivity analyses. The findings for the exposures were fairly consistent across the studies with modest evidence of heterogeneity. Our study has several limitations, as well. Although case-control studies are subject to recall bias, it is unlikely to have a major effect herein because CLL/ SLL has very few established risk factors. All studies used the older CLL/SLL diagnostic criteria that required absolute lymphocyte count more than 5 × 10 9 cells/L compared with the new 2008 criteria of B-cell lymphocyte count more than 5 × 10 9 cells/L. Under the new diagnostic change, at least a third of the Rai stage 0 CLL/ SLL cases are reclassified to monoclonal B-cell lymphocytosis, a precursor condition to CLL/SLL (2). Although our sample size is large (even after accounting for the misclassification of cases), it is possible that some of our novel findings are due to chance.
Overall, the results of this pooled analysis provide additional evidence that a number of exposures are associated with CLL/ SLL risk and that these exposures are independent of each other. A number of the exposures are not modifiable (e.g., race/ethnicity, sex, family history, height, and atopy), whereas some potentially modifiable exposures may decrease risk (e.g., UV radiation), whereas others may increase risk (e.g., farm exposures and hair products). Further studies are needed to confirm our smoking and transfusion findings, as well as detailed studies evaluating occupational exposures of farming and hairdressers. The biologic basis for these associations remains to be elucidated; however, our findings support that genetic factors, immune function, and infection have a role in CLL/SLL leukemogenesis. Given that CLL/SLL has more than 30 susceptibility loci identified to date (38) (39) (40) (41) (42) , studies evaluating the interaction among these genetic and nongenetic factors is warranted.
